Professor, Director of the Head and Neck Oncology Program, Emory University
Oncology
Dr. Nabil F. Saba, MD
|
|
Give Review
Nabil Saba works in the field of Oncology. He received awards:"Distinguished Doctor", "Top Doctor", "Outstanding Contribution To Fellowship Program", "Atlanta Magazine: Top Doctors" and "Fellow (FACP)". Dr. Nabil F. Saba is a published doctor. He published 71 publications, including: 'Metastatic signet-ring cell adenocarcinoma to the urinary bladder.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic Carcinoma and for nonadenoid cystic malignant salivary tumors.
- ACR Appropriateness Criteria(®) Aggressive Nonmelanomatous Skin Cancer of the Head and Neck.
- Is there a role for PET/CT parameters to differentiate thyroid cartilage invasion from penetration?
- Targeting HER (ERBB) signaling in head and neck Cancer: An essential update.
- A novel prediction model for human papillomavirus-associated oropharyngeal squamous Cell carcinoma using p16 and subCellular β-catenin expression.
- Fatigue is associated with inflammation in patients with head and neck Cancer before and after intensity-modulated radiation therapy.
- A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous Cell carcinoma.
- Predictors and outcomes of venous thromboembolism in hospitalized lung Cancer patients: A Nationwide Inpatient Sample database analysis.
- Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database Analysis.
- 18F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual Analysis of PET and contrast enhanced CT better than the numbers?
- A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.
- Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous Cell carcinoma of the head and neck.
- Current treatment of T1N0 squamous Cell carcinoma of the glottic larynx.
- Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous Cell carcinomas of the head and neck (SCCHN): a systematic review.
- Human papillomavirus 16 oncoprotein regulates the translocation of β-catenin via the activation of epidermal growth factor receptor.
- Mutation and Transcriptional Profiling of Formalin-Fixed Paraffin Embedded Specimens as Companion Methods to Immunohistochemistry for Determining Therapeutic Targets i...
- Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous Cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradia...
- Pre-medications for cetuximab induced infusion reactions - Commentary.
- ACR Appropriateness Criteria® thyroid Carcinoma.
- Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma (HNSCC).
- Chemoprevention of head and neck Cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.
- Lymph node ratio influences risk of head and neck Cancer loco-regional recurrence after initial surgical resection: Implications for adjuvant therapy.
- Accuracy of Computed Tomography for Predicting Pathologic Nodal Extracapsular Extension in Patients With Head-and-Neck Cancer Undergoing Initial Surgical Resection.
- Targeted therapies in metastatic esophageal Cancer: Advances over the past decade.
- Incidence and prognosis of gastroesophageal Cancer in rural, urban, and metropolitan areas of the United States.
- Acetylated Tubulin (AT) as a Prognostic Marker in Squamous Cell Carcinoma of the Head and Neck.
- Paranasal sinus squamous Cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results Data, 1973 to 2009.
- ACR Appropriateness Criteria(®) Treatment of Stage 1 T1 Glottic Cancer.
- Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non-Small-Cell Lung Cancer.
- Reply, Contralateral irradiation for T(limited) N2bM0 lateralized tonsil Cancer.
- Risk Factors for Rising Incidence of Esophageal and Gastric Cardia AdenoCarcinoma.
- Monoclonal Antibodies against Epidermal Growth Factor Receptor in Solid Tumors.
- Advances in Targeting HER3 as an AntiCancer Therapy.
- EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab.
- Antiepidermal Growth Factor Receptor Therapy in Squamous Cell Carcinoma of the Head and Neck.
- Comparison of quantum dot technology with conventional immunohistochemistry in examining aldehyde dehydrogenase 1A1 as a potential biomarker for lymph node metastasis ...
- Patterns of extralaryngeal spread of laryngeal Cancer: Thyroid Cartilage Penetration Occurs in a Minority of Patients with Extralaryngeal Spread of Laryngeal Squamous ...
- Concurrent chemotherapy with intensity-modulated radiation therapy for locally advanced squamous Cell carcinoma of the larynx and oropharynx: a retrospective single-in...
- Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous Cell carcinoma.
- Optimizing systemic therapy in squamous Cell carcinoma of the head and neck with a focus on targeted agents.
- Examining expression of folate receptor in squamous Cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug.
- Moving toward bioadjuvant approaches to head and neck Cancer prevention.
- Targeting the epidermal growth factor receptor. Trials in head and neck and lung Cancer.
- Chemoprevention strategies for patients with lung Cancer in the context of screening.
- Gender and ethnic disparities in incidence and survival of squamous Cell carcinoma of the oral tongue, base of tongue, and tonsils: a surveillance, epidemiology and en...
- Targeting angiogenesis in head and neck Cancer.
- Simultaneous occurrence of polycythemia vera and Waldenstrom macroglobulinemia: a case report and review of the literature.
- Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous Cell carcinoma: predictive and prognostic...
- The role of bisphosphonates in the management of advanced Cancer with a focus on non-small-cell lung Cancer. Part 1: Mechanisms of action, role of biomarkers and precl...
- The role of bisphosphonates in the management of advanced Cancer with a focus on non-small-cell lung Cancer. Part 2: Clinical studies and economic analyses.
- Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall Cell lung c...
- Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.
- Novel targeted agents in the treatment of lung Cancer.
- Percutaneous feeding tubes in patients with head and neck Cancer: rethinking prophylactic placement for patients undergoing chemoradiation.
- Chemoprevention in lung Cancer.
- ACR Appropriateness Criteria(®) Retreatment of Recurrent Head and Neck Cancer After Prior Definitive Radiation Expert Panel on Radiation Oncology-Head and N...
- ACR appropriateness criteria® adjuvant therapy for resected squamous Cell carcinoma of the head and neck.
- Retinoids as chemoprevention for head and neck Cancer: where do we go from here?
- ACR Appropriateness Criteria: local-regional therapy for resectable oropharyngeal squamous Cell carcinomas.
- Molecular biological design of novel antineoplastic therapies.
- Technology evaluation: mapatumumab, Human Genome Sciences/GlaxoSmithKline/Takeda.
- Intra-cranial lesions in a patient with Hodgkin Lymphoma.
- Bone marrow transplantation for nonmalignant Diseases.
- Rosai-Dorfman Disease of the epiglottis.
- Targeted therapies in small-cell lung Cancer.
- Sickle blood contains tissue factor-positive microparticles derived from endothelial Cells and monocytes.
- Metastatic signet-ring Cell adenocarcinoma to the urinary bladder.
- Overview of autologous stem Cell transplantation.
- Real-World Effectiveness of Systemic Agents Approved for Advanced Non-Small Cell Lung Cancer: A SEER-Medicare Analysis.
- Targeting epidermal growth factor receptor for head and neck squamous Cell carcinoma: still lost in translation?
Schools
American University Of Beirut
Faulkner Hospital
Roger Williams Hospital
University Of Wi Hospital and Cli
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Amerigroup (Wellpoint)
- Blue Card PPO
- Blue Choice HMO
- Blue Choice Option POS
- Blue Open Access POS
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- Golden Rule
- GEHA
- Choice Care PPO
- Preferred PPO
- Kaiser Permanente
- Mail Handlers Benefit Plan (MHBP)
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Distinguished Doctor
- Top Doctor
- Outstanding Contribution To Fellowship Program
- Atlanta Magazine: Top Doctors
- Fellow (FACP)
Education
-
Brown University -
University of Wisconsin -
American University of Beirut Faculty of Medicine
Hospital
-
Emory University Hospital
Drug Facts
| NPI NUMBER | 1558479188 | |
| NPPES Provider LastName | SABA | |
| NPPES Provider FirstName | NABIL | |
| NPPES Provider ZIPCode | 303221013 | |
| NPPES Provider State | GA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 835.0 | |
| Distinct Opioid Count | 8.0 | |
| Opioid Claim Count | 226.0 | |
| Percent Opioid Claims | 27.07 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1558479188 |
| Last Name Of The Provider | SABA |
| First Name Of The Provider | NABIL |
| View All |
Similar Doctors
|
|
Dr. Michael P. Fanucchi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Fadlo R. Khuri, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Eric R. Anderson, MD |
|
|
Dr. Fuad El Rassi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donald J. Filip, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ruth M. O'Regan, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Amelia B. Zelnak, MD
This Doctor is OpenDoctor Recommended.
|